Exclusion Criteria:~* Any clinically relevant neurological disorder capable of producing a dementia syndrome
including Parkinson's disease, stroke, vascular dementia, dementia with Lewy bodies, frontotemporal dementia
and others.~* 4 or more micro-hemorrhages (amyloid-related imaging abnormalities - hemorrhage type (ARIA-H) on
baseline MRI or any evidence of amyloid-related imaging abnormalities - effusion type (ARIA-E) (Sperling et al,
2011).~* History of malignancy within the past five years with the exception of basal cell or squamous cell
cancer, in-situ cervical cancer, or localized prostate cancer.~* History of seizure in the past three years
prior to randomization~* Any contraindication of having brain MRI~* Any contraindication of having PET
(inability to lie flat and still for the duration of the scan, intolerance to previous PET such as
hypersensitivity reaction to PET ligand or imaging agent)~* The subject has any unstable medical illness
including hypertension, congestive heart failure, chronic obstructive pulmonary disease, renal failure, liver
failure or other organ compromise.~* Other clinically important abnormality on vital signs, physical
examination, neurologic examination, laboratory results, or electrocardiogram (ECG) examination (e.g. Atrial
fibrillation) that could compromise the study or be detrimental to the subject.~* The subject has received
bexarotene previously.~* The subject has an allergy to bexarotene.~* Has had a PET scan in the past 12
months.~* Has had radiotherapy in the past year.~* Have participated in an investigational drug or device study
within 30 days prior to Visit 2.~* Have been treated with immunomodulators to treat AD (vaccines, antibodies
etc) within 6 months prior to visit 2~* Unable to swallow uncrushed oral medication in capsule form~* Have any
condition or reason that, in the opinion of the investigator, which could interfere with the ability of the
patients to participate or complete the trials, or places the patient at undue risk or complicates the
interpretation of safety or efficacy data.
